ejpmr, 2024, 12(1), 436-444

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

FINERENONE: A BREAKTHROUGH IN THE MANAGEMENT OF DIABETIC KIDNEY DISEASE

Sandhra R. Nair*, Lathika A. Nayak and A. R. Shabharaya

Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Post Farangipete, Mangalore-574143.

***Corresponding Author: Sandhra R. Nair**

Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Post Farangipete, Mangalore-574143.

Article Received on 26/11/2024 **Article Revised on 16/12/2024** **Article Accepted on 06/01/2025**

ABSTRACT

Nonsteroidal mineralocorticoid receptor antagonists (MRAs) offer a promising therapeutic alternative in cardiorenal diseases, addressing the shortcomings of steroidal MRAs. A non-steroidal selective MRA, finerenone shows promise in halting the decline of renal function in chronic kidney disease (CKD) with diabetes mellitus (DM), lowering albuminuria and lowering hyperkalemia, and improving cardiovascular outcomes by lowering heart failure episodes. The effectiveness of finerenone in enhancing kidney and cardiovascular (CV) outcomes was demonstrated by clinical trials, such as FIDELIO-DKD and FIGARO-DKD. On finerenone, patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) had lower rates of cardiovascular events, such as heart attack hospitalization. However, these trials focused on asymptomatic or early-stage HF and excluded patients with symptoms.In addition to offering insights into the present and future of cardiorenal disease management, this review attempts to provide a thorough overview of the mechanisms and clinical evaluation of nonsteroidal MRA finerenone. Clinical trials of finerenone in patients with nondiabetic kidney disease are still underway, but the evidence supporting its beneficial effect in the range of cardiorenal diseases is currently limited to the findings of studies done on T2DM patients. Nonsteroidal MRAs have a great deal of promise as key therapeutic targets for a variety of heart conditions.

KEYWORDS: finerenone, diabetic kidney disease, cardiorenal disease, mineralocorticoid receptor antagonist, heart failure.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a metabolic condition marked by hyperglycaemia due to insulin resistance. The management of Type 2 Diabetes Mellitus necessitates a multifaceted approach using both behavioural and pharmaceutical interventions to avert or postpone problems and enhance quality of life. Chronic kidney disease (CKD) and cardiovascular disease (CVD) are prevalent consequences of type 2 diabetes mellitus (T2DM).[1] In patients with T2DM, cardiovascular problems are the primary cause of morbidity and mortality, whereas renal consequences are notably prevalent. Therapeutic methods that impede the advancement of chronic kidney disease (CKD) and the onset of cardiovascular disease (CVD) comprise angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), sodium-glucose co-transporter 2 inhibitors (SGLT-2i), and GLP-1 receptor agonists (GLP-1RA). Mineralocorticoid receptors (MRs) are extensively located in the heart, kidneys, brain, lungs, colon, skin, liver, skeletal muscle, saliva, sweat glands, and adipose tissue. Mineralocorticoid receptors (MRs) are mostly expressed in the cardiovascular system and kidneys, and they are crucial in ventricular remodeling and the progression of chronic heart failure (CHF). Aldosterone, the MR, regulates sodium and potassium homeostasis and maintains the body's electrolyte balance. Furthermore, a growing body of research indicates that the inflammatory and fibrotic effects are mediated by the excessive activation of mineralocorticoid receptors, resulting in detrimental cardiac and renal consequences. It may be a significant therapeutic target for CKD resulting from T2DM.[2]

The primary physiological ligands of mineralocorticoid receptors (MR) are aldosterone and cortisol. MR is expressed in various tissues and cells, including cardiomyocytes, vascular endothelial cells, vascular smooth muscle cells, renal tubular epithelial cells, and macrophages. Aldosterone interacts with MR in the distal renal tubular epithelial cells to create an aldosterone-MR complex, facilitating sodium reabsorption and the excretion of potassium and hydrogen ions. This indicates that MR is crucial in regulating water and salt balance, blood pressure, and circulating blood volume. MRAs directly bind to and inhibit MR, preventing aldosterone or 11-

deoxycorticosterone from activating them, therefore diminishing inflammation and cardiac remodeling.[3] MRAs are categorized as specific or non-specific according to their chemical classification. Specific MRAs are non-steroidal, whereas nonspecific MRAs are steroidal. Initially identified non-specific MRAs gained widespread utilization owing to their metabolic regulation properties as potent anti-mineralocorticoids, mild anti-androgens, and weak anti-steroidogenesis agents. These medications obstruct the actions of androgens by inhibiting the receptors activated by testosterone and dihydrotestosterone. The anti-androgenic action of spironolactone renders it a treatment option for polycystic ovarian syndrome and acne.[4]

Steroidal mineralocorticoid receptor antagonists (MRAs), specifically spironolactone and eplerenone, induce antihypertensive effects and mitigate the advancement of chronic kidney disease (CKD). However, their clinical utilization is constrained by adverse effects such as hyperkalemia, gynecomastia, impotence, and amenorrhea. Consequently, recent innovations have focused on creating nonsteroidal mineralocorticoid receptor antagonists with a strong affinity for the mineralocorticoid receptor to reduce the undesirable side effects associated with steroidal antagonists. In 2021, the Food and Drug Administration (FDA) approved finerenone, thereby introducing the first nonsteroidal mineralocorticoid antagonist (MRA) to the market. Nonsteroidal mineralocorticoid receptor antagonists are presently being evaluated for their effectiveness in heart failure and their possible synergistic application with sodium-glucose cotransporter 2 inhibitors. These innovative drugs provide potential as a substantial therapeutic alternative within the cardiorenal illness continuum.[5]

NON-STEROIDAL SELECTIVE MRA-FINERENONE

Finerenone is a selective non-steroidal mineralocorticoid receptor antagonist (MRA) that has become an important treatment option for individuals with chronic kidney disease (CKD) linked to type 2 diabetic mellitus (T2DM). Its distinctive characteristics and modes of action differentiate it from conventional steroidal mineralocorticoid receptor antagonists such as spironolactone and eplerenone. Finerenone received FDA approval in July 2021 and EMA approval in March 2022, fulfilling the urgent demand for effective treatments to alleviate the detrimental impacts of MR overactivation, especially in patients with T2DM, who face heightened risks of renal and cardiovascular decline.[6] Chronic kidney disease is marked by a gradual deterioration of renal function, frequently aggravated by comorbidities including diabetes and hypertension. The mineralocorticoid receptor (MR), chiefly stimulated by aldosterone, is essential for the regulation of sodium and potassium equilibrium, blood pressure, and fluid homeostasis. Excessive activation of MR might result in adverse effects such as inflammation, fibrosis, and further renal deterioration. This underscores the necessity of creating targeted treatments that can efficiently suppress MR signaling pathways while avoiding the adverse effects linked to conventional steroidal MRAs.[7]

Finerenone's distinctive chemical composition differentiates it from conventional steroidal mineralocorticoid receptor antagonists such as spironolactone and eplerenone. Its non-steroidal characteristics facilitate enhanced selectivity and efficacy in inhibiting MR activation. Finerenone precisely targets the mineralocorticoid receptor (MR), offering a therapeutic strategy that diminishes inflammation and fibrosis while reducing side effects such hyperkalemia, a frequent issue associated with older medications.[8]

MECHANISM OF ACTION

Finerenone's mechanism of action encompasses multiple essential molecular processes. Initially, it attaches to the mineralocorticoid receptor (MR) with significant affinity, functioning as a "bulky" antagonist. This binding obstructs the receptor's capacity to undergo conformational alterations essential for activation by aldosterone. Typically, when aldosterone attaches to mineralocorticoid receptors in renal epithelial cells, it initiates a series of processes resulting in sodium reabsorption and potassium excretion.[9] Finerenone efficiently inhibits this mechanism by obstructing aldosterone from triggering the conformational alterations necessary for receptor activation. Upon binding to MR, finerenone obstructs the recruitment of transcriptional co-activators necessary for commencing the transcription of target genes linked to salt retention, inflammation, and fibrosis. This blockage results in reduced production of pro-inflammatory cytokines, including IL-6, and profibrotic factors like as TGF-β. Finerenone mitigates inflammation and fibrosis in target organs, including the kidneys and heart, by obstructing these pathways, hence offering protective benefits against organ damage. The effect of finerenone is most pronounced in illnesses such as chronic kidney disease (CKD) and heart failure, where MR activity is frequently heightened due to increased aldosterone levels or other influences. Finerenone mitigates disease development by antagonizing MR signaling pathways, hence conserving renal function and enhancing cardiovascular outcomes.[10]

PHARMACOKINETICS

Optimizing finerenone's therapeutic use in clinical practice requires a deep comprehension of its pharmacokinetics. After oral administration, finerenone exhibits a bioavailability of approximately 50%. Peak plasma concentrations are generally attained within 0.5 to 0.75 hours post-dosing. This rapid absorption profile facilitates prompt therapeutic effects. Finerenone demonstrates widespread distribution across bodily tissues owing to its lipophilic characteristics. The volume of distribution signifies extensive tissue distribution

rather than confinement within the vascular compartment. Moreover, finerenone exhibits an elevated level of protein binding (approximately 99%), predominantly associating with albumin and alpha-1 acid glycoprotein.[11]The metabolism of finerenone is essential to its pharmacological characteristics. It is predominantly metabolized by the cytochrome P450 enzyme CYP3A4. In contrast to certain other medications that generate substantial active metabolites, finerenone lacks significant active metabolites; consequently, its pharmacological effects are primarily ascribed to the unchanged drug concentrations in circulation. Clinicians must consider potential drug interactions when prescribing finerenone in conjunction with other medications that either induce or inhibit CYP3A4, given this metabolic pathway. Finerenone possesses an elimination half-life of approximately 2 hours under standard conditions. Approximately 80% of the administered dose is excreted via feces (mainly as metabolites), whereas roughly 20% is eliminated through urine. This elimination profile guides dosing decisions; consistent monitoring of serum potassium levels is recommended due to possible electrolyte imbalances.[12]

DOSING CONSIDERATIONS

Clinicians must consider various factors pertaining to dosing and patient management when prescribing finerenone. The suggested initial dosage for adults is generally 10 mg once daily, subject to modification according to individual patient response and tolerability. For patients with moderate renal impairment (eGFR between 30–59 mL/min), dose modifications may be required based on clinical assessment. Monitoring is essential when commencing treatment with finerenone. Routine evaluations of serum potassium concentrations are recommended due to the potential for hyperkalemia, particularly in individuals with chronic kidney disease or those receiving medications that influence potassium levels. Clinicians must periodically assess renal function during treatment to ensure appropriate dosing modifications.[13]

CLINICAL EFFICACY

The clinical efficacy of finerenone has been validated through multiple pivotal trials that highlight its role in the management of chronic kidney disease associated with type 2 diabetes mellitus. The FIDELIO-DKD trial assessed the impact of finerenone on renal outcomes in individuals with chronic kidney disease associated with type 2 diabetes mellitus. This multicenter trial encompassed patients with an eGFR ranging from 25 to 60 mL/min and an elevated urinary albumin-to-creatinine ratio (UACR). The findings indicated that finerenone markedly diminished the risk of kidney failure or a sustained decrease in eGFR relative to placebo, while concurrently lowering albuminuria, a critical indicator of renal impairment. The FIGARO-DKD trial evaluated cardiovascular outcomes in conjunction with renal protection. This trial involved a comparable patient population but concentrated on major adverse cardiovascular events (MACE). The findings revealed that finerenone was linked to a substantial decrease in major adverse cardiovascular events (MACE) compared to placebo, while also exhibiting advantages in the preservation of renal function over time. These trials collectively underscore finerenone's dual function in safeguarding renal function and cardiovascular health in high-risk populations—an essential consideration due to the interconnectedness of these conditions.[13]

CLINICAL EVIDENCE SUPPORTING FINERENONE IN DIABETIC KIDNEY DISEASE (DKD)

KEY CLINICAL TRIALS

FIDELIO-DKD Trial

The FIDELIO-DKD trial was a phase III, randomized, double-blind study designed to evaluate the impact of finerenone on renal and cardiovascular outcomes in patients with diabetic kidney disease (DKD) marked by albuminuria. The trial included 5,734 participants diagnosed with type 2 diabetes, possessing an estimated glomerular filtration rate (eGFR) ranging from 25 to 60 mL/min/1.73 m², all exhibiting elevated urinary albumin-to-creatinine ratios (UACR).[14] Patients had to be on the highest tolerated doses of either an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) prior to randomization for treatment with either finerenone or a placebo. The principal endpoint of the trial was a composite of a sustained decline in eGFR of 40% or greater, renal failure, or renal mortality. Secondary endpoints encompassed cardiovascular outcomes, including cardiovascular mortality, non-fatal myocardial infarction, and hospitalization due to heart failure. The findings demonstrated that finerenone markedly decreased the occurrence of the primary composite outcome relative to placebo, yielding a hazard ratio of 0.82 (95% confidence interval [CI], 0.73–0.93). Furthermore, a significant decrease in cardiovascular events was observed in participants administered finerenone, underscoring its dual advantage in renal and cardiovascular safeguarding.[15]

FIGARO-DKD Trial

The FIGARO-DKD trial expanded the scope of finerenone's evaluation by including a broader population of DKD patients with varying degrees of kidney function and albuminuria. This phase III trial aimed to assess the safety and efficacy of finerenone in reducing cardiovascular events among patients with type 2 diabetes and chronic kidney disease who were already receiving optimal renin-angiotensin system (RAS) blockade therapy. In FIGARO-DKD, patients were randomized to receive either finerenone or placebo, with the primary endpoint being a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure. The trial demonstrated that finerenone significantly reduced the risk of the primary cardiovascular composite outcome compared to placebo. Importantly, it also

showed a reduction in new-onset heart failure among patients without a history of heart failure at baseline. The results from FIGARO-DKD complement those from FIDELIO-DKD by confirming the cardiovascular benefits of finerenone across a wider spectrum of CKD severity.[16]

EFFICACY OUTCOMES

Finerenone's impact on kidney function has been notably positive in both key trials. In FIDELIO-DKD, there was a significant reduction in albuminuria levels among patients treated with finerenone compared to placebo. This reduction in albuminuria is clinically relevant as it correlates strongly with long-term renal outcomes; indeed, meta-regression analyses suggest that changes in albuminuria can predict reductions in kidney failure risk. In terms of glomerular filtration rate (GFR), finerenone treatment was associated with a slower decline in eGFR compared to placebo over the study period. The pooled analysis from both FIDELIO-DKD and FIGARO-DKD confirmed these findings, showing that finerenone consistently improved both renal and cardiovascular outcomes across various patient populations within the studies. Regarding cardiovascular outcomes, finerenone has shown benefits beyond just renal protection. In both trials, there was a significant reduction in major adverse cardiovascular events (MACE), including strokes and hospitalizations for heart failure.[17] This dual action—protecting both renal function and reducing cardiovascular risk—positions finerenone as a valuable therapeutic option for managing DKD.

SAFETY PROFILE

While finerenone demonstrates significant efficacy, its safety profile is also critical for clinical consideration. The most common adverse event associated with finerenone is hyperkalemia, which was observed more frequently than in the placebo group. In FIDELIO-DKD, hyperkalemia led to discontinuation of treatment in some cases; however, careful monitoring allows for effective management of potassium levels. Other adverse events included hypotension and renal events; however, these were not significantly higher than those observed in the placebo group. Importantly, when compared to traditional treatments such as ACE inhibitors and ARBs, finerenone's safety profile appears favorable regarding hyperkalemia incidence. In clinical practice, this means that while monitoring potassium levels is essential when prescribing finerenone, it may be safer than older MRAs for certain patient populations. In summary, both the FIDELIO-DKD and FIGARO-DKD trials provide compelling evidence supporting the use of finerenone in diabetic kidney disease. Its ability to reduce progression to kidney failure while simultaneously lowering cardiovascular risks underscores its potential as a cornerstone therapy for patients with DKD. With ongoing research into its long-term effects and combination therapies involving SGLT2 inhibitors, finerenone is poised to play an increasingly important role in managing this challenging condition.[18]

CLINICAL IMPACT OF FINERENONE ON DIABETIC KIDNEY DISEASE (DKD)

REDUCTION IN KIDNEY DISEASE PROGRESSION

Finerenone has demonstrated a robust ability to slow the progression of kidney disease in patients with DKD. In the FIDELIO-DKD trial, finerenone significantly reduced the risk of composite kidney outcomes, including sustained declines in estimated glomerular filtration rate (eGFR) and kidney failure. Specifically, the trial reported a hazard ratio of 0.82 (95% CI, 0.73–0.93) for the primary composite outcome, which included kidney failure or renal death, indicating a substantial reduction in the risk of kidney failure progression among patients treated with finerenone compared to placebo. Additionally, finerenone was effective in lowering albuminuria levels, a critical marker for renal damage and a strong predictor of long-term renal outcomes. The reduction in albuminuria and slower decline in eGFR observed with finerenone treatment contribute to delaying the need for dialysis and other interventions associated with advanced kidney disease. This is particularly significant for patients with DKD, who are at high risk for rapid disease progression.[19]

CARDIOVASCULAR BENEFITS

The cardiovascular benefits of finerenone are equally noteworthy. In the FIGARO-DKD trial, finerenone was associated with a significant reduction in major adverse cardiovascular events (MACE), including heart failure hospitalization and all-cause mortality. The trial reported a hazard ratio of 0.87 (95% CI, 0.76–0.98) for cardiovascular events when comparing finerenone to placebo. Specifically, patients receiving finerenone experienced an 18% lower risk of cardiovascular death or first hospitalization for heart failure compared to those on placebo. Furthermore, there was a notable reduction in the incidence of heart failure hospitalization among patients treated with finerenone, reinforcing its potential as a therapeutic agent that not only protects renal function but also reduces cardiovascular morbidity and mortality in patients with DKD.[20]

BENEFITS IN VARIOUS SUBGROUPS

Finerenone's efficacy extends across various patient subgroups, making it a versatile treatment option for DKD management. Evidence from both FIDELIO-DKD and FIGARO-DKD indicates that finerenone provides consistent benefits regardless of baseline characteristics such as blood pressure levels or stage of kidney disease. Finerenone's efficacy is further supported by its performance in patients receiving background therapy with SGLT2 inhibitors or renin-angiotensin system (RAS) blockers. Both trials demonstrated that finerenone provided additional benefits on top of standard therapies. For example, in patients already treated with SGLT2 inhibitors, finerenone continued to show significant reductions in UACR and improved renal outcomes compared to placebo. This suggests that finerenone can be safely integrated into existing treatment regimens

without compromising safety or efficacy. Additionally, subgroup analyses indicated that the benefits of finerenone were consistent regardless of whether patients were on background therapy with ACE inhibitors or ARBs.[14] The reduction in cardiovascular events and kidney failure risk was maintained across these subgroups, highlighting finerenone's role as a complementary therapy in managing DKD alongside other established treatments.

COMPARISON WITH OTHER THERAPIES

Finerenone has emerged as a significant therapeutic option for patients with diabetic kidney disease (DKD), particularly in comparison to traditional mineralocorticoid receptor antagonists (MRAs), angiotensin-converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARBs). Its unique properties and mechanisms of action offer distinct advantages in managing DKD and its associated complications.

FINERENONE VS. TRADITIONAL MRAS (SPIRONOLACTONE, EPLERENONE)

One of the primary advantages of finerenone over traditional steroidal MRAs like spironolactone and eplerenone is its selectivity for the mineralocorticoid receptor. Finerenone is designed to selectively inhibit the MR without significant activity on other steroid hormone receptors, which reduces the risk of side effects commonly associated with steroidal MRAs, such as hyperkalemia and gynecomastia. Studies have shown that finerenone has a lower incidence of treatment-related hyperkalemia compared to spironolactone, making it a safer option for patients with compromised renal function or those at risk for electrolyte imbalances. Furthermore, finerenone's unique binding mechanism allows it to exert anti-inflammatory and anti-fibrotic effects more effectively than traditional MRAs. This results in improved cardiovascular and renal outcomes in patients with DKD, as evidenced by the results from the FIDELIO-DKD and FIGARO-DKD trials, which demonstrated that finerenone significantly reduced albuminuria and slowed kidney disease progression compared to placebo.[21]

FINERENONE VS. ACE INHIBITORS AND ARBS

When comparing finerenone to ACE inhibitors and ARBs, it is essential to consider efficacy, safety, and side effect profiles. Both ACE inhibitors and ARBs are cornerstones in managing hypertension and preventing kidney disease progression in patients with diabetes. However, despite their effectiveness, these agents do not fully address the mineralocorticoid receptor's role in promoting renal damage through inflammation and fibrosis. Finerenone has been shown to provide additional benefits when used alongside ACE inhibitors or ARBs. In the FIDELIO-DKD trial, patients receiving finerenone demonstrated a significant reduction in composite kidney outcomes while already being treated with optimized doses of ACE inhibitors or ARBs. This indicates that finerenone can enhance the protective effects of RAS blockade therapy. In terms of safety, finerenone has a favorable side effect profile compared to traditional MRAs. While ACE inhibitors and ARBs can cause cough, angioedema, and hyperkalemia, finerenone presents a lower risk of these adverse events.[22] The combination of these therapies may offer a synergistic effect on renal protection while minimizing overall side effects.

COMBINATION THERAPY

The potential for combining finerenone with other agents, such as SGLT2 inhibitors, is another area of interest in improving kidney and cardiovascular outcomes in DKD patients. SGLT2 inhibitors have shown efficacy in reducing heart failure hospitalization and slowing CKD progression by promoting glycemic control and diuresis. When used together with finerenone, there is potential for additive benefits. Recent studies suggest that the combination of SGLT2 inhibitors and finerenone may lead to enhanced reductions in albuminuria and improved renal outcomes compared to either agent alone.[23] This combination therapy approach could be particularly beneficial for patients who remain at high risk for cardiovascular events despite treatment with RAS blockers or SGLT2 inhibitors alone.

EFFICACY IN DIFFERENT STAGES OF DKD

Finerenone's efficacy extends across different stages of diabetic kidney disease, making it a versatile treatment option. Evidence from clinical trials demonstrates that finerenone effectively reduces the risk of CKD progression regardless of the baseline stage of kidney disease. In both FIDELIO-DKD and FIGARO-DKD trials, patients at various stages of CKD experienced significant improvements in renal outcomes when treated with finerenone. For early-stage DKD patients, finerenone can help delay the progression to more advanced stages by reducing albuminuria and slowing eGFR decline. In advanced DKD cases, where the risk of kidney failure is heightened, finerenone's ability to mitigate inflammation and fibrosis may provide critical protective effects against further deterioration.[24]

SAFETY AND TOLERABILITY OF FINERENONE

ADVERSE EVENTS

The most notable adverse event associated with finerenone is hyperkalemia, which refers to elevated potassium levels in the blood. Hyperkalemia poses a significant risk, particularly in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as it can lead to serious complications such as cardiac arrhythmias. In clinical trials, the incidence of hyperkalemia was higher in patients treated with finerenone compared to those receiving placebo. Specifically, the FIDELIO-DKD trial reported that hyperkalemia led to treatment discontinuation in some patients, although the overall rate of discontinuation due to this side effect remained relatively low compared to traditional MRAs like spironolactone and eplerenone. In

addition to hyperkalemia, other common side effects include gastrointestinal symptoms such as nausea and diarrhea, as well as fatigue and headache. Importantly, unlike traditional MRAs, finerenone has not been associated with sexual side effects such as gynecomastia or menstrual irregularities.[25] This favorable side effect profile enhances its tolerability among patients who may be sensitive to these issues.

RISK MITIGATION STRATEGIES

To manage the risk of hyperkalemia and other potential side effects associated with finerenone, several best practices can be implemented.

Monitoring Potassium Levels: Regular monitoring of serum potassium levels is essential for patients on finerenone. It is recommended that potassium levels be checked before initiating treatment and periodically thereafter—typically within the first month of therapy and then every 3 to 6 months. More frequent monitoring may be warranted for patients with renal impairment or those on concurrent medications that can increase potassium levels.[26]

Dose Adjustment: If hyperkalemia occurs (usually defined as a potassium level greater than 5.5 mEq/L), clinicians may need to adjust the dose of finerenone or temporarily discontinue therapy until potassium levels normalize. In some cases, the use of potassium-reducing agents (e.g., sodium polystyrene sulfonate) may also be necessary to manage elevated potassium levels effectively.[27]

Patient Education: Educating patients about the signs and symptoms of hyperkalemia is crucial. Patients should be instructed to report any unusual symptoms such as muscle weakness, palpitations, or significant fatigue immediately. Additionally, dietary counseling regarding potassium intake may also be beneficial.

LONG-TERM SAFETY DATA

Long-term safety data from clinical trials suggest that finerenone is generally well-tolerated over extended periods. In both the FIDELIO-DKD and FIGARO-DKD trials, which included diverse populations with comorbidities such as diabetes and hypertension, finerenone demonstrated a favorable safety profile even after prolonged use.

Tolerability Over Time: The incidence of hyperkalemia remained consistent throughout the studies without a significant increase over time. Most adverse events were mild to moderate in severity and resolved with appropriate management strategies.[28]

Impact on Comorbidities: In patients with comorbid conditions such as diabetes and hypertension—common in those with DKD—finerenone's long-term use did not exacerbate these conditions compared to placebo. The drug's ability to reduce albuminuria and slow CKD progression while maintaining a manageable safety profile makes it a suitable option for long-term management in high-risk populations.[29]

ECONOMIC AND QUALITY OF LIFE IMPACT OF FINERENONE

COST-EFFECTIVENESS

The cost-effectiveness of finerenone in the treatment of DKD has been evaluated through various studies, particularly in the context of its addition to standard of care (SoC). For instance, a study conducted in the Netherlands utilized a Markov cohort model to simulate the disease pathway of patients with CKD and type 2 diabetes (T2D). The findings indicated that adding finerenone to SoC resulted in a reduction of total lifetime costs by approximately €6,136 per patient while extending quality-adjusted life years (QALYs) by 0.20 compared to SoC alone. This established finerenone as a dominant treatment option with an 83% probability of being cost-effective at a willingness-to-pay threshold of €20,000 per QALY.Similarly, a study conducted in China found that finerenone combined with SoC yielded a QALY gain of 0.321 compared to SoC alone, with total costs per patient being lower under the finerenone + SoC regimen (381,130 CNY vs. 392,390 CNY). The analysis concluded that finerenone + SoC was a dominant treatment strategy, demonstrating substantial economic advantages alongside clinical benefits. Moreover, the FIGARO-DKD trial demonstrated that finerenone effectively reduced major adverse cardiovascular events by 14% and kidney composite outcomes by 22%, further supporting its economic viability by potentially lowering costs related to hospitalizations and advanced renal intervention. These findings underscore the potential for finerenone to reduce healthcare costs associated with CKD complications, including hospitalizations and dialysis.[30]

IMPACT ON PATIENT QUALITY OF LIFE

Finerenone's ability to improve patient quality of life is closely linked to its effectiveness in slowing disease progression and preventing complications such as end-stage renal disease (ESRD). By reducing albuminuria and delaying declines in renal function, finerenone helps maintain kidney health longer, which translates into fewer symptoms and complications for patients. In clinical trials, patients treated with finerenone reported improvements in overall well-being due to reduced hospitalizations related to cardiovascular events and renal replacement therapy. The extension of time free from serious health events contributes positively to patients' quality of life, as they experience fewer disruptions caused by their condition.[31] The improvement in QALYs observed in various studies reflects these enhancements in health-related quality of life.

HEALTHCARE SYSTEM IMPACT

The broader implications of finerenone on healthcare systems are significant. By effectively slowing the

progression of DKD and reducing the incidence of complications such as dialysis initiation and kidney transplants, finerenone can lead to substantial cost savings for healthcare systems. Studies indicate that preventing ESRD not only improves patient outcomes but also reduces the financial burden on healthcare resources associated with dialysis treatments and transplant procedures. Each dialysis treatment incurs considerable costs, including hospitalizations and ongoing outpatient care. By delaying or preventing the need for these interventions through effective management with finerenone, healthcare systems can realize significant savings.[32]

FUTURE DIRECTIONS AND RESEARCH ON FINERENONE

ONGOING CLINICAL TRIALS

Several ongoing clinical trials are investigating finerenone's role in DKD and its effectiveness in combination therapies. One notable trial is the FINE-ONE study, which aims to evaluate the efficacy of finerenone in patients with type 1 diabetes and chronic kidney disease (CKD). This trial focuses on measuring changes in albuminuria over six months, using albuminuria as a bridging biomarker for regulatory approval. If successful, finerenone could expand its indication for kidney protection from type 2 diabetes to type 1 diabetes, potentially benefiting a broader patient population. Additionally, the FINEARTS-HF trial is examining the effects of finerenone in patients with heart failure and CKD. This trial will provide insights into finerenone's efficacy in reducing cardiovascular events in patients with overlapping cardiorenal conditions. The results from these trials will be crucial in determining the broader applicability of finerenone beyond its current indications.[33]

EXPANSION TO OTHER KIDNEY DISEASES

Beyond its established use in DKD, there is growing interest in exploring finerenone's potential for treating other forms of kidney disease, such as hypertensive nephropathy and chronic kidney disease due to other etiologies. The emerging understanding of mineralocorticoid receptor overactivation's role in various kidney diseases suggests that finerenone may offer therapeutic benefits across a broader spectrum of renal conditions. Research indicates that finerenone may help mitigate renal damage associated with hypertension by reducing inflammation and fibrosis, which are common pathological features in various forms of CKD. Ongoing studies will be essential to validate these hypotheses and determine finerenone's effectiveness in these population.[34]

PERSONALIZED TREATMENT APPROACHES

The future of finerenone therapy may also involve personalized treatment approaches guided by precision medicine and biomarkers. Identifying specific biomarkers that predict responses to finerenone can help tailor treatment plans for individual patients based on their unique profiles. For instance, albuminuria has been established as a strong predictor of renal outcomes, and its reduction has been associated with improved long-term kidney function. By utilizing biomarkers such as albuminuria levels or genetic markers related to mineralocorticoid receptor signaling, clinicians may better select patients who are most likely to benefit from finerenone therapy.[35]

POTENTIAL FOR ADJUNCTIVE THERAPIES

Exploring the role of finerenone in combination with other emerging treatments presents an exciting avenue for enhancing therapeutic outcomes in DKD. For example, combining finerenone with sodium-glucose cotransporter-2 (SGLT2) inhibitors has shown promise in improving both renal and cardiovascular outcomes due to their complementary mechanisms of action. Additionally, innovative approaches such as gene therapy or stem cell therapy may eventually be integrated into treatment regimens alongside finerenone. These adjunctive therapies could further enhance the management of DKD by addressing underlying pathophysiological mechanisms while finerenone provides symptomatic relief and slows disease progression.[36]

CONCLUSION

Finerenone represents a significant breakthrough in the management of diabetic kidney disease (DKD), demonstrating substantial effectiveness in reducing kidney disease progression and improving cardiovascular outcomes. The results from pivotal clinical trials, including FIDELIO-DKD and FIGARO-DKD, have shown that finerenone not only lowers the risk of major adverse cardiovascular events but also significantly reduces the progression of kidney disease in patients with type 2 diabetes, with a 20% reduction in composite kidney outcomes and a 14% reduction in cardiovascular events. This dual benefit underscores its potential to transform DKD management and alleviate the burden of dialysis and kidney transplants. However, further studies are needed to refine finerenone's role in DKD management and establish its long-term clinical benefits across diverse populations. Ongoing clinical trials assessing finerenone's efficacy in combination therapies and its application in other forms of kidney disease will be essential for understanding its full potential. As we continue to explore the multifaceted benefits of finerenone, investing in research will be imperative to solidify its place as a cornerstone therapy for managing DKD and improving patient quality of life.

REFERENCE

1. Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med, 2024; 30(12): 3758-3764. doi:10.1038/s41591-024-03264-4

2. Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship?. Curr Cardiol Rev, 2019; 15(1): 55-63. doi:10.2174/1573403X14666180711124825
3. Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacol Rev, 2016; 68(1): 49-75. doi:10.1124/pr.115.011106
4. Igbekele AE, Jia G, Hill MA, Sowers JR, Jia G. Mineralocorticoid Receptor Activation in Vascular Insulin Resistance and Dysfunction. Int J Mol Sci., 2022; 23(16): 8954. Published 2022 Aug 11. doi:10.3390/ijms23168954
5. Shah M, Awad AS, Abdel-Rahman EM. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease. J Clin Med, 2023; 12(19): 6285. Published 2023 Sep 29. doi:10.3390/jcm12196285
6. Marcath LA. Finerenone. Clin Diabetes, 2021; 39(3): 331-332. doi:10.2337/cd21-0050
7. Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem, 2012; 7(8): 1385-1403. doi:10.1002/cmdc.201200081
8. Amazit L, Le Billan F, Kolkhof P, et al. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. J Biol Chem, 2015; 290(36): 21876-21889. doi:10.1074/jbc.M115.657957
9. Lv R, Xu L, Che L, Liu S, Wang Y, Dong B. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front Endocrinol (Lausanne), 2023; 14: 1125693. Published 2023 Feb 13. doi:10.3389/fendo.2023.1125693
10. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med, 2020; 383(23): 2219-2229. doi:10.1056/NEJMoa2025845
11. Goldman JD. Optimizing Finerenone in People With Diabetes and Chronic Kidney Disease: An Opportunity for the Pharmacist. J Pharm Pract, 2024; 37(6): 1374-1379. doi:10.1177/08971900241256725
12. Ashjian E, Clarke M, Pogue K. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes. Am J Health Syst Pharm, 2023; 80(23): 1708-1721. doi:10.1093/ajhp/zxad192
13. Kawaguchi Y, Hajika Y, Ashida N, et al. Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study. Metabol Open, 2024; 24: 100318. Published 2024 Sep 7. doi:10.1016/j.metop.2024.100318
14. Chiu N, Aggarwal R, Bakris GL, Pitt B, Bhatt DL. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc, 2022; 11(7): e025079. doi:10.1161/JAHA.121.025079
15. Heerspink HJL, Birkenfeld AL, Cherney DZI, et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract, 2023; 204: 110908. doi:10.1016/j.diabres.2023.110908
16. Filippatos G, Anker SD, Agarwal R, et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation, 2022; 145(6): 437-447. doi:10.1161/CIRCULATIONAHA.121.057983
17. Zhang MZ, Bao W, Zheng QY, Wang YH, Sun LY. Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol, 2022; 13: 819327. Published 2022 Feb 7. doi:10.3389/fphar.2022.819327
18. Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA, 2015; 314(9): 884-894. doi:10.1001/jama.2015.10081
19. Toth-Manikowski S, Atta MG. Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. J Diabetes Res, 2015; 2015: 697010. doi:10.1155/2015/697010
20. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med, 2021; 385(24): 2252-2263. doi:10.1056/NEJMoa2110956
21. Palanisamy S, Funes Hernandez M, Chang TI, Mahaffey KW. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist. Cardiol Ther, 2022; 11(3): 337-354. doi:10.1007/s40119-022-00269-3
22. González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med, 2023; 55(1): 502-513. doi:10.1080/07853890.2023.2171110
23. Arici M, Altun B, Araz M, et al. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Front Med (Lausanne), 2024; 11: 1384454. Published 2024 Jun 14. doi:10.3389/fmed.2024.1384454
24. DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab, 2022; 24(7): 1197-1205. doi:10.1111/dom.14696
25. Yasmin F, Aamir M, Najeeb H, et al. Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and

meta-analysis. Ann Med Surg (Lond), 2023; 85(10): 4973-4980. Published 2023 Aug 16. doi:10.1097/MS9.0000000000001180
26. Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol, 2016; 30(2): 172-184. doi:10.1111/fcp.12170
27. Rossing P, Anker SD, Filippatos G, et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care, 2022; 45(12): 2991-2998. doi:10.2337/dc22-0294
28. Górriz JL, González-Juanatey JR, Facila L, Soler MJ, Valle A, Ortiz A. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease. Nefrologia (Engl Ed), 2023; 43(4): 386-398. doi:10.1016/j.nefroe.2023.09.002
29. Arici M, Altun B, Araz M, et al. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Front Med (Lausanne), 2024; 11: 1384454. Published 2024 Jun 14. doi:10.3389/fmed.2024.1384454
30. Quist SW, van Schoonhoven AV, Bakker SJL, et al. Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands. Cardiovasc Diabetol, 2023; 22(1): 328. Published 2023 Nov 28. doi:10.1186/s12933-023-02053-6
31. Di Lullo L, Lavalle C, Scatena A, Mariani MV, Ronco C, Bellasi A. Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. J Clin Med, 2023; 12(12): 3992. Published 2023 Jun 12. doi:10.3390/jcm12123992
32. González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med, 2023; 55(1): 502-513. doi:10.1080/07853890.2023.2171110
33. Shaikh A, Ray J, Campbell KN. Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. Ther Clin Risk Manag, 2022; 18: 753-760. Published 2022 Jul 29. doi:10.2147/TCRM.S325916
34. Escobar Vasco MA, Fantaye SH, Raghunathan S, Solis-Herrera C. The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease. Diabetes Obes Metab, 2024; 26(10): 4135-4146. doi:10.1111/dom.15773
35. Singh AK, Farag YMK, Zheng Z, Bakris GL. Clinical trial designs of emerging therapies for diabetic kidney disease (DKD). Postgrad Med, 2024; 136(6): 585-593. doi:10.1080/00325481.2024.2377529
36. Wang N, Zhang C. Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression. Int J Mol Sci, 2024; 25(6): 3086. Published 2024 Mar 7. doi:10.3390/ijms25063086